Pulmonx Corp. LUNG 深 滬
已收盤 05-08 16:00:00 美东时间
1.26
-0.010
-0.79%
華盛通- 最 高1.3005
- 今 開1.27
- 成交量 60.59万股
- 最 低 1.22
- 昨 收 1.27
- 總市值 5321.89万
- 52周最高 3.88
- 市盈率 靜 --
- 換手率 1.43%
- 52周最低 1.13
- 委 比 61.23%
- 總股本 4223.72万
- 歷史最高 69.478
- 量 比 0.87
- 振 幅 6.34%
- 歷史最低 1.13
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Summary: Pulmonx Q4
The Q4 earnings report for Pulmonx (NASDAQ:LUNG) was released on Wednesday, Mar...
03-05 05:10
Pulmonx Sees FY2026 Sales $90.000M-$92.000M vs $94.227M Est
Pulmonx (NASDAQ:LUNG) sees FY2026 sales of $90.000 million-$92.000 million vs $94.227 million analyst estimate.
03-05 05:09
Pulmonx Q4 EPS $(0.25) Beats $(0.39) Estimate, Sales $22.598M Beat $21.728M Estimate
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39) by 36.22 percent. This is a 24.24 percent increase over losses of $(0.33) per share from the same
03-05 05:08
Pulmonx Announces Closing of up to $60 Million Credit Facility
Pulmonx Corporation announced the closing of a $60 million five-year credit facility with Perceptive Advisors to refinance its existing debt and provide additional capital through 2027. The facility includes an initial $40 million term loan and an option to draw an additional $20 million, subject to revenue milestones. The new facility, which is interest-only until 2031, features favorable terms that strengthen the company’s capital structure. Pu...
03-04 21:05
Earnings Scheduled For March 4, 2026
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
D. Boral Capital Maintains Buy on Pulmonx, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains Pulmonx (NASDAQ:LUNG) with a Buy and maintains $14 price target.
02-20 21:06
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx Corporation announced it will release its 2025 Q4 and full year financial results on March 4, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. The company, a leader in minimally invasive lung treatments, offers products like the Zephyr® Endobronchial Valve for severe emphysema/COPD patients.
02-20 13:00
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation granted equity awards totaling 1,625,000 shares to two new hires in Q4 2025, including Chief Financial Officer and Chief Operating Officer Derrick Sung. 1,225,000 RSUs were awarded, with 1,200,000 allocated to Sung. RSUs vest over four years, with 25% vesting at one year and the rest in quarterly installments. Additionally, Sung received up to 400,000 PSUs, subject to time-based vesting over three years and a performance condi...
2025-12-03 21:05
